- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Nuvectis Pharma Q2 Loss Widens From Higher Costs, Shares Down | 2 | RTTNews | ||
| Di | Nuvectis Pharma, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| Di | Nuvectis Pharma, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| Di | Nuvectis Pharma, Inc.: Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights | 329 | GlobeNewswire (Europe) | Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group ("Haisco"), transforming the company into a late-stage clinical... ► Artikel lesen | |
| 23.07. | China approves Nuvectis' ciprocopan for blood disorder PNH | 1 | Investing.com | ||
| 23.07. | China erteilt Zulassung für Nuvectis-Medikament Ciprocopan zur Behandlung der Blutkrankheit PNH | 1 | Investing.com Deutsch | ||
| 23.07. | Nuvectis Pharma, Inc.: Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors | 247 | GlobeNewswire (Europe) | First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from Haisco's broad completed clinical development program... ► Artikel lesen | |
| NUVECTIS PHARMA Aktie jetzt für 0€ handeln | |||||
| 14.07. | Wall Street Wire: StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data | 665 | Newsfile | New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease player following its June licensing deal with Haisco... ► Artikel lesen | |
| 08.07. | Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High? | 2 | Zacks | ||
| 30.06. | Nuvectis Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.06. | Kapitalerhöhung mit hohem Abschlag: Nuvectis Pharma Aktie bricht um 25 % ein | 3 | Investing.com Deutsch | ||
| 30.06. | Nuvectis Pharma shares slide 19% on pricing of $100M stock offering | 1 | Seeking Alpha | ||
| 30.06. | Nuvectis Pharma prices $100 million public offering at $20/share | 3 | Investing.com | ||
| 30.06. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock | 2 | GlobeNewswire (USA) | ||
| 29.06. | Nuvectis Pharma announces public share offering to support drug programs | 1 | Seeking Alpha | ||
| 29.06. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 26.06. | What Makes Nuvectis Pharma (NVCT) a New Buy Stock | 1 | Zacks | ||
| 24.06. | Haisco and Nuvectis sign licensing deal for two drugs | 3 | Pharmaceutical Technology | ||
| 23.06. | Haisco lizenziert Wirkstoffkandidaten an Nuvectis - 40 Millionen US-Dollar Sofortzahlung | 14 | Investing.com Deutsch | ||
| 23.06. | Haisco licenses two drug candidates to Nuvectis for $40m upfront | 1 | Investing.com |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 6,850 | -0,29 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 7,770 | 0,00 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,094 | -0,91 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,281 | +2,18 % | Der Weg zur Klinik: Wie Finanzierung Biotech-Erfolge ermöglicht | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,021 | -0,39 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,595 | +0,83 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| ONCO-INNOVATIONS | 0,400 | -0,99 % | Onco-Innovations Limited: Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010's API | VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of its... ► Artikel lesen | |
| NOVOCURE | 13,700 | -3,32 % | Novocure Reports Second Quarter 2026 Financial Results | Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications
CE Mark received for Optune Paxfor the treatment of locally... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,700 | -3,14 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights | Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 3,140 | +0,32 % | Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial | ||
| PALISADE BIO | 2,110 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis | ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,803 | 0,00 % | Oncolytics Biotech, Inc.: Oncolytics Biotech Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial | Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential... ► Artikel lesen | |
| OUTLOOK THERAPEUTICS | 0,886 | -0,11 % | XFRA 41O: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| REGENXBIO | 9,000 | -2,93 % | REGENXBIO Inc.: REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights | RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027
Long-term surabgene lomparvovec... ► Artikel lesen | |
| OMEROS | 11,200 | -2,18 % | Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA | Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company's marketing... ► Artikel lesen |
Das Unternehmen NUVECTIS PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,05 % bei einem Aktienkurs von 18,940 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NUVECTIS PHARMA INC finden Sie auf Wallstreet Online.